Mobilise App IPO GMP Today: Grey Market Premium & Subscription Update

The Mobilise App Lab IPO continues to attract investor attention as its subscription period closes on February 25, 2026. This SME‑grade offering is generating notable interest in the grey market, with positive sentiment reflected in the Grey Market Premium (GMP) figures leading up to the listing. As investors closely follow subscription data and potential listing gains, here is the latest update on the IPO and how it is faring in the market ahead of its debut.

Mobilise App Lab Limited is launching this IPO to raise funds for its ongoing growth strategy. The issue size is approximately ₹20.10 Crore, with the entire amount raised through fresh equity shares. The IPO opened for subscription on February 23, 2026 and will close today, February 25, 2026, giving investors a short window to participate in this offering.

The company has set the price band at ₹75 to ₹80 per share, with each share carrying a face value of ₹10. Investors must apply in lots of 1,600 shares, which comes to a significant minimum application value for retail participants. Once the subscription is complete, the allotment date is scheduled for February 26, 2026, with refunds processed shortly after. The allotment will be credited to demat accounts before the listing date on March 2, 2026, when the shares begin trading on the NSE SME platform.

What the Grey Market Says

A key indicator that market watchers use to gauge pre‑listing sentiment is the Grey Market Premium (GMP). This unofficial measure reflects investor expectations and how much premium traders are willing to pay above the IPO price before the actual listing occurs. For the Mobilise App IPO, the GMP has shown fluctuations over the subscription period. As of February 25, 2026, the GMP stands at roughly ₹8, indicating an expected listing price of around ₹88 per share — nearly 10 percent above the upper price band of ₹80.

Earlier in the subscription period, the GMP had been as high as ₹16, suggesting strong pre‑listing enthusiasm. On some days, the grey market values dipped to ₹7, but overall sentiment remains positive. These movements reflect how investor expectations have shifted in the days leading up to the IPO’s close.

While GMP is widely used by traders and investors to estimate potential listing gains, it is important to note that it operates outside official stock exchanges and is not regulated. As a result, GMP should be seen as an indicator of sentiment rather than a guarantee of listing performance. Factors like actual subscription figures, company fundamentals, market conditions, and broader investor demand ultimately determine the listing price.

Subscription Status and Demand

The subscription for the IPO has been strong so far. According to reports, the issue saw multiples of subscription within the first few days, indicating that both retail and non‑institutional investors are actively participating. By Day 2, the Mobilise App Lab IPO had already garnered over 12 times subscription, demonstrating robust demand for the offering. The higher interest in the IPO may also support positive GMP trends and can contribute to a more favorable listing debut.

Different investor categories — including qualified institutional buyers (QIBs), non‑institutional investors (NIIs), and retail investors — are allocated portions of the IPO. This allocation structure aims to balance participation across different investor groups and improve overall subscription quality.

Company Overview

Founded in the early 2010s, Mobilise App Lab Limited specializes in software solutions and digital platforms catering to educational institutions and enterprises. The company’s flagship product — EduPro ERP — is a management system for schools, colleges, and training centers that handles admissions, attendance, fees, exams, transport logistics, and other academic operations.

Over time, the company has expanded its product suite to include multiple enterprise software solutions such as CMMS (maintenance management), SCMPro (supply chain), HRevO (human resources), AI Studio, and IoT‑enabled applications. The portfolio reflects a focus on cloud‑based and scalable platforms that enable businesses to streamline operations and enhance digital workflows.

With a growing focus on SaaS (Software as a Service) and technology innovation, Mobilise App Lab has positioned itself within a competitive and expanding segment of the Indian IT ecosystem. Its solutions appeal to sectors that seek automation and improved operational efficiency, which can support long‑term growth for the company.

What Investors Should Consider

Despite positive GMP figures and subscription momentum, prospective investors should evaluate multiple factors before investing in the IPO. SME IPOs — especially those in the technology services and SaaS domain — can be volatile and depend heavily on future performance, earnings growth, and market adoption of products. Investors should consider reviewing the company’s financials, revenue growth trends, and competitive positioning before making investment decisions.

Grey Market Premium numbers can provide a snapshot of short‑term sentiment, but they are not a substitute for a comprehensive review of company fundamentals. Consulting financial advisors and comparing the IPO against peer offerings can help investors make informed choices based on risk tolerance and investment objectives.

Final Thoughts

As the Mobilise App Lab IPO closes on February 25, 2026, investor focus will now shift to allotment outcomes and the anticipated listing on March 2, 2026. With a GMP of about ₹8, there may be modest listing gains if sentiment remains strong, though actual results will depend on broader market dynamics and subscription strength. Investors should keep an eye on allotment announcements and official listing price movements in the coming days.

In summary, the Mobilise App IPO has garnered solid interest and offers insight into small‑cap tech IPO demand in the current market climate. Whether you are a first‑time IPO investor or a seasoned market participant, evaluating both the GMP and deeper company fundamentals can guide more informed investment decisions.